OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer that are underserved by available therapies. Using a proven structure-based drug design platform, we are building a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become the leader in targeting oncogenic PI3Kα and has multiple programs to enable optimal targeting of this critical oncogene.
